Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 8 | 2024 | 688 | 2.910 |
Why?
|
| Wearable Electronic Devices | 6 | 2024 | 62 | 2.360 |
Why?
|
| Cannabis | 3 | 2023 | 51 | 2.220 |
Why?
|
| Telemedicine | 5 | 2024 | 313 | 2.100 |
Why?
|
| Craving | 3 | 2024 | 36 | 1.700 |
Why?
|
| Cannabinoids | 3 | 2023 | 38 | 1.680 |
Why?
|
| Opioid-Related Disorders | 9 | 2024 | 457 | 1.510 |
Why?
|
| Drug Overdose | 6 | 2023 | 126 | 1.500 |
Why?
|
| Substance Abuse Detection | 3 | 2016 | 44 | 1.450 |
Why?
|
| Fat Emulsions, Intravenous | 4 | 2015 | 37 | 1.400 |
Why?
|
| Biosensing Techniques | 5 | 2017 | 113 | 1.160 |
Why?
|
| Mobile Applications | 5 | 2024 | 129 | 1.160 |
Why?
|
| Stress, Psychological | 2 | 2024 | 445 | 1.150 |
Why?
|
| Cocaine | 4 | 2015 | 99 | 1.070 |
Why?
|
| Monitoring, Ambulatory | 3 | 2016 | 56 | 1.060 |
Why?
|
| Analgesics, Opioid | 9 | 2024 | 492 | 0.990 |
Why?
|
| Machine Learning | 3 | 2022 | 156 | 0.840 |
Why?
|
| Analgesics, Non-Narcotic | 2 | 2019 | 35 | 0.800 |
Why?
|
| Hallucinogens | 1 | 2022 | 14 | 0.770 |
Why?
|
| Smartphone | 4 | 2024 | 67 | 0.760 |
Why?
|
| Toxicology | 2 | 2024 | 33 | 0.750 |
Why?
|
| Circulating MicroRNA | 1 | 2019 | 5 | 0.660 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 42 | 0.640 |
Why?
|
| Acetaminophen | 1 | 2019 | 49 | 0.630 |
Why?
|
| Emergency Service, Hospital | 9 | 2024 | 1024 | 0.560 |
Why?
|
| Systems Integration | 1 | 2017 | 26 | 0.550 |
Why?
|
| Glass | 1 | 2017 | 22 | 0.550 |
Why?
|
| Transducers | 1 | 2017 | 26 | 0.540 |
Why?
|
| Transcriptome | 1 | 2019 | 345 | 0.530 |
Why?
|
| Humans | 33 | 2024 | 59737 | 0.520 |
Why?
|
| Hemodynamics | 2 | 2013 | 231 | 0.490 |
Why?
|
| Secondary Prevention | 1 | 2016 | 153 | 0.490 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 82 | 0.470 |
Why?
|
| Social Media | 1 | 2017 | 116 | 0.470 |
Why?
|
| Pilot Projects | 7 | 2021 | 922 | 0.440 |
Why?
|
| Male | 20 | 2024 | 27952 | 0.430 |
Why?
|
| Research Design | 1 | 2017 | 556 | 0.430 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2013 | 14 | 0.430 |
Why?
|
| Epinephrine | 1 | 2013 | 41 | 0.430 |
Why?
|
| Vasoconstrictor Agents | 1 | 2013 | 64 | 0.410 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2060 | 0.390 |
Why?
|
| Adult | 13 | 2024 | 15771 | 0.390 |
Why?
|
| Naloxone | 3 | 2023 | 57 | 0.390 |
Why?
|
| Skin | 1 | 2015 | 359 | 0.380 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 791 | 0.380 |
Why?
|
| Galvanic Skin Response | 3 | 2016 | 23 | 0.370 |
Why?
|
| Biomedical Research | 3 | 2024 | 257 | 0.350 |
Why?
|
| Heart Rate | 3 | 2020 | 309 | 0.340 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 121 | 0.330 |
Why?
|
| Buprenorphine | 2 | 2023 | 182 | 0.330 |
Why?
|
| Financing, Government | 2 | 2020 | 30 | 0.330 |
Why?
|
| Pain Management | 2 | 2024 | 146 | 0.320 |
Why?
|
| Young Adult | 4 | 2024 | 4290 | 0.300 |
Why?
|
| Female | 15 | 2024 | 30925 | 0.290 |
Why?
|
| Middle Aged | 8 | 2024 | 16449 | 0.290 |
Why?
|
| Acute Pain | 2 | 2017 | 17 | 0.280 |
Why?
|
| Emergency Medicine | 2 | 2020 | 182 | 0.280 |
Why?
|
| Child | 3 | 2022 | 4215 | 0.280 |
Why?
|
| Oxycodone | 2 | 2017 | 30 | 0.270 |
Why?
|
| Faculty, Medical | 2 | 2019 | 192 | 0.270 |
Why?
|
| Logistic Models | 2 | 2021 | 1240 | 0.270 |
Why?
|
| Skin Temperature | 2 | 2016 | 18 | 0.260 |
Why?
|
| Fractures, Bone | 2 | 2017 | 136 | 0.250 |
Why?
|
| Wrist | 2 | 2016 | 33 | 0.250 |
Why?
|
| Self Report | 2 | 2020 | 360 | 0.240 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 577 | 0.240 |
Why?
|
| Adolescent | 3 | 2021 | 5866 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 810 | 0.230 |
Why?
|
| Sentinel Surveillance | 1 | 2024 | 17 | 0.220 |
Why?
|
| Dronabinol | 1 | 2023 | 31 | 0.210 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 127 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1570 | 0.210 |
Why?
|
| Random Allocation | 2 | 2013 | 190 | 0.210 |
Why?
|
| Rats | 4 | 2013 | 1911 | 0.210 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 142 | 0.200 |
Why?
|
| Psychometrics | 1 | 2024 | 363 | 0.200 |
Why?
|
| Research Support as Topic | 2 | 2019 | 39 | 0.200 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2020 | 111 | 0.200 |
Why?
|
| Cannabinoid Receptor Agonists | 1 | 2022 | 5 | 0.200 |
Why?
|
| Mentors | 2 | 2020 | 115 | 0.190 |
Why?
|
| Cholinergic Antagonists | 2 | 2019 | 33 | 0.190 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2023 | 119 | 0.180 |
Why?
|
| Tertiary Healthcare | 1 | 2021 | 13 | 0.180 |
Why?
|
| Aged | 5 | 2024 | 13510 | 0.180 |
Why?
|
| Seizures | 1 | 2022 | 115 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2013 | 498 | 0.180 |
Why?
|
| Decision Making | 1 | 2024 | 395 | 0.180 |
Why?
|
| Drug Users | 1 | 2021 | 28 | 0.170 |
Why?
|
| Eating | 1 | 2021 | 132 | 0.170 |
Why?
|
| Geographic Information Systems | 1 | 2020 | 20 | 0.170 |
Why?
|
| Wireless Technology | 1 | 2020 | 18 | 0.170 |
Why?
|
| Time Factors | 2 | 2019 | 3629 | 0.160 |
Why?
|
| Cardiotonic Agents | 1 | 2019 | 50 | 0.160 |
Why?
|
| Hypnotics and Sedatives | 1 | 2019 | 62 | 0.160 |
Why?
|
| United States | 5 | 2024 | 7448 | 0.160 |
Why?
|
| Research Personnel | 1 | 2020 | 92 | 0.160 |
Why?
|
| Mindfulness | 1 | 2020 | 66 | 0.160 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 357 | 0.150 |
Why?
|
| Efficiency | 1 | 2018 | 38 | 0.150 |
Why?
|
| Medication Adherence | 2 | 2017 | 243 | 0.150 |
Why?
|
| Naltrexone | 1 | 2019 | 77 | 0.150 |
Why?
|
| Writing | 1 | 2018 | 41 | 0.150 |
Why?
|
| Medical Informatics Applications | 1 | 2017 | 14 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 213 | 0.140 |
Why?
|
| Incidence | 1 | 2021 | 1245 | 0.140 |
Why?
|
| Alcoholism | 1 | 2020 | 310 | 0.140 |
Why?
|
| Telemetry | 1 | 2017 | 19 | 0.140 |
Why?
|
| Music Therapy | 1 | 2017 | 17 | 0.140 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 55 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 943 | 0.130 |
Why?
|
| Prognosis | 1 | 2021 | 1613 | 0.130 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1038 | 0.130 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2017 | 96 | 0.130 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 727 | 0.130 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 63 | 0.130 |
Why?
|
| Forecasting | 1 | 2017 | 223 | 0.130 |
Why?
|
| Equipment Design | 1 | 2017 | 334 | 0.130 |
Why?
|
| Registries | 1 | 2019 | 805 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2017 | 117 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2016 | 75 | 0.120 |
Why?
|
| Motion | 1 | 2015 | 56 | 0.120 |
Why?
|
| Locomotion | 1 | 2016 | 111 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2020 | 3090 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1511 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 141 | 0.120 |
Why?
|
| Body Temperature | 1 | 2015 | 45 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 1289 | 0.120 |
Why?
|
| Chronic Pain | 1 | 2017 | 136 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 456 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2021 | 6153 | 0.120 |
Why?
|
| Infant | 1 | 2019 | 1496 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2019 | 850 | 0.110 |
Why?
|
| Algorithms | 1 | 2020 | 981 | 0.110 |
Why?
|
| Biomarkers | 1 | 2019 | 1315 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 1802 | 0.110 |
Why?
|
| Animals | 5 | 2015 | 19705 | 0.110 |
Why?
|
| Pain | 1 | 2017 | 398 | 0.110 |
Why?
|
| Anticholinergic Syndrome | 1 | 2013 | 1 | 0.110 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.110 |
Why?
|
| Atropine | 1 | 2013 | 13 | 0.110 |
Why?
|
| Sodium Chloride | 1 | 2013 | 60 | 0.110 |
Why?
|
| Antithrombins | 1 | 2013 | 14 | 0.110 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2013 | 28 | 0.110 |
Why?
|
| Blood Coagulation | 1 | 2013 | 38 | 0.110 |
Why?
|
| Muscarinic Antagonists | 1 | 2013 | 32 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 54 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 531 | 0.100 |
Why?
|
| Cyclohexylamines | 1 | 2012 | 5 | 0.100 |
Why?
|
| Mitragyna | 1 | 2012 | 5 | 0.100 |
Why?
|
| Salvia | 1 | 2012 | 3 | 0.100 |
Why?
|
| Cyclohexanones | 1 | 2012 | 5 | 0.100 |
Why?
|
| Alkaloids | 1 | 2012 | 11 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2013 | 259 | 0.090 |
Why?
|
| Piperazines | 1 | 2012 | 74 | 0.090 |
Why?
|
| Kinetics | 1 | 2013 | 751 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2019 | 5334 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 804 | 0.090 |
Why?
|
| Psychotropic Drugs | 1 | 2012 | 81 | 0.090 |
Why?
|
| Electrocardiography | 1 | 2013 | 524 | 0.090 |
Why?
|
| Risk Factors | 1 | 2019 | 5011 | 0.080 |
Why?
|
| Massachusetts | 1 | 2015 | 2027 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 5147 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 2520 | 0.060 |
Why?
|
| Fever | 1 | 2024 | 63 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2024 | 104 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2023 | 25 | 0.050 |
Why?
|
| Focus Groups | 1 | 2024 | 289 | 0.050 |
Why?
|
| Community Health Services | 1 | 2023 | 120 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2024 | 339 | 0.050 |
Why?
|
| Prescriptions | 1 | 2022 | 31 | 0.050 |
Why?
|
| Hospitals | 1 | 2024 | 380 | 0.040 |
Why?
|
| Opiate Substitution Treatment | 1 | 2023 | 188 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2024 | 620 | 0.040 |
Why?
|
| Phenotype | 1 | 2024 | 1142 | 0.040 |
Why?
|
| Academies and Institutes | 1 | 2019 | 21 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2020 | 29 | 0.040 |
Why?
|
| Trauma Centers | 1 | 2019 | 114 | 0.040 |
Why?
|
| Capsules | 1 | 2017 | 34 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 471 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 311 | 0.040 |
Why?
|
| Pain Perception | 1 | 2017 | 7 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2017 | 25 | 0.030 |
Why?
|
| Radio Waves | 1 | 2017 | 18 | 0.030 |
Why?
|
| Drug Approval | 1 | 2017 | 25 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 940 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 113 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2017 | 85 | 0.030 |
Why?
|
| Affect | 1 | 2017 | 123 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 527 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2017 | 329 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 355 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2017 | 330 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 361 | 0.030 |
Why?
|
| Bleeding Time | 1 | 2013 | 4 | 0.030 |
Why?
|
| Dabigatran | 1 | 2013 | 20 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 166 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 354 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 694 | 0.020 |
Why?
|